The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine

Prevention of hepatitis B virus (HBV) infection by vaccination can potentially eliminate HBV-related diseases. PreHevbrio™/PreHevbri® is a 3-antigen (S, preS1, preS2) HBV vaccine (3A-HBV) recently licensed for adults in the US, EU and Canada. This study evaluated antibody persistence in a subset of...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-06, Vol.41 (24), p.3584-3588
Main Authors: Vesikari, T., Langley, J.M., Spaans, J.N., Petrov, I., Popovic, V., Yassin-Rajkumar, B., Anderson, D.E., Diaz-Mitoma, F.
Format: Article
Language:English
Subjects:
(5-10): 3-antigen
Adult
Age
Anti-HBs
Antibodies
Antigens
Body mass index
HBV
Hepatitis
Hepatitis B
Hepatitis B - prevention & control
Hepatitis B Antibodies
Hepatitis B Surface Antigens
Hepatitis B Vaccines
Hepatitis B virus
Humans
Immunologic Memory
Persistence
Regression analysis
Seroprotection
Statistical analysis
Vaccination
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prevention of hepatitis B virus (HBV) infection by vaccination can potentially eliminate HBV-related diseases. PreHevbrio™/PreHevbri® is a 3-antigen (S, preS1, preS2) HBV vaccine (3A-HBV) recently licensed for adults in the US, EU and Canada. This study evaluated antibody persistence in a subset of fully vaccinated and seroprotected (anti-HBs ≥ 10 mIU/mL) Finnish participants from the phase 3 trial (PROTECT) of 3A-HBV versus single-antigen HBV vaccine (1A-HBV). 465/528 eligible subjects were enrolled (3A-HBV: 244; 1A-HBV: 221). Baseline characteristics were balanced. After 2.5 years, more 3A-HBV subjects remained seroprotected (88.1 % [95 %CI: 84.1,92.2]) versus 1A-HBV (72.4 % [95 %CI: 66.6,78.3)], p 
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2023.05.010